{"doi":"10.1016\/j.addr.2007.05.011","coreId":"137056","oai":"oai:bradscholars.brad.ac.uk:10454\/4844","identifiers":["oai:bradscholars.brad.ac.uk:10454\/4844","10.1016\/j.addr.2007.05.011"],"title":"Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.","authors":["Blagden, Nicholas","De Matas, Marcel","Gavan, P. T.","York, Peter"],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"30\/07\/2007","abstract":"noThe increasing prevalence of poorly soluble drugs in development provides notable risk of new products demonstrating low and erratic\\ud\nbioavailabilty with consequences for safety and efficacy, particularly for drugs delivered by the oral route of administration. Although numerous\\ud\nstrategies exist for enhancing the bioavailability of drugs with low aqueous solubility, the success of these approaches is not yet able to be\\ud\nguaranteed and is greatly dependent on the physical and chemical nature of the molecules being developed. Crystal engineering offers a number of\\ud\nroutes to improved solubility and dissolution rate, which can be adopted through an in-depth knowledge of crystallisation processes and the\\ud\nmolecular properties of active pharmaceutical ingredients. This article covers the concept and theory of crystal engineering and discusses the\\ud\npotential benefits, disadvantages and methods of preparation of co-crystals, metastable polymorphs, high-energy amorphous forms and ultrafine\\ud\nparticles. Also considered within this review is the influence of crystallisation conditions on crystal habit and particle morphology with potential\\ud\nimplications for dissolution and oral absorption","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":null,"rawRecordXml":"<record><header><identifier>\n        \n            \n                oai:bradscholars.brad.ac.uk:10454\/4844<\/identifier><datestamp>\n                2014-05-19T14:20:44Z<\/datestamp><setSpec>\n                com_10454_152<\/setSpec><setSpec>\n                col_10454_6342<\/setSpec>\n            <\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:doc=\"http:\/\/www.lyncode.com\/xoai\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:title>\n            \nCrystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.<\/dc:title><dc:creator>\nBlagden, Nicholas<\/dc:creator><dc:creator>\nDe Matas, Marcel<\/dc:creator><dc:creator>\nGavan, P. T.<\/dc:creator><dc:creator>\nYork, Peter<\/dc:creator><dc:subject>\nCrystal engineering<\/dc:subject><dc:subject>\nCrystallisation<\/dc:subject><dc:subject>\nSupramolecular chemistry<\/dc:subject><dc:subject>\nPolymorphism<\/dc:subject><dc:subject>\nCo-crystal<\/dc:subject><dc:subject>\nSolubility<\/dc:subject><dc:subject>\nDissolution rate<\/dc:subject><dc:subject>\nBioavailability<\/dc:subject><dc:subject>\nLow aqueous solubility<\/dc:subject><dc:description>\nno<\/dc:description><dc:description>\nThe increasing prevalence of poorly soluble drugs in development provides notable risk of new products demonstrating low and erratic\\ud\nbioavailabilty with consequences for safety and efficacy, particularly for drugs delivered by the oral route of administration. Although numerous\\ud\nstrategies exist for enhancing the bioavailability of drugs with low aqueous solubility, the success of these approaches is not yet able to be\\ud\nguaranteed and is greatly dependent on the physical and chemical nature of the molecules being developed. Crystal engineering offers a number of\\ud\nroutes to improved solubility and dissolution rate, which can be adopted through an in-depth knowledge of crystallisation processes and the\\ud\nmolecular properties of active pharmaceutical ingredients. This article covers the concept and theory of crystal engineering and discusses the\\ud\npotential benefits, disadvantages and methods of preparation of co-crystals, metastable polymorphs, high-energy amorphous forms and ultrafine\\ud\nparticles. Also considered within this review is the influence of crystallisation conditions on crystal habit and particle morphology with potential\\ud\nimplications for dissolution and oral absorption.<\/dc:description><dc:date>\n2011-03-21T16:57:31Z<\/dc:date><dc:date>\n2011-03-21T16:57:31Z<\/dc:date><dc:date>\n30\/07\/2007<\/dc:date><dc:type>\nArticle<\/dc:type><dc:identifier>\nBlagden, N., De Matas, M., Gavan, P. T. and York, P. (2007). Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Advanced drug delivery reviews. Vol. 59, No. 7, pp. 617-630.<\/dc:identifier><dc:identifier>\n90004827<\/dc:identifier><dc:identifier>\n90015954<\/dc:identifier><dc:identifier>\n90008331<\/dc:identifier><dc:identifier>\nhttp:\/\/hdl.handle.net\/10454\/4844<\/dc:identifier><dc:language>\nen<\/dc:language><dc:relation>\nhttp:\/\/dx.doi.org\/10.1016\/j.addr.2007.05.011<\/dc:relation>\n<\/oai_dc:dc>\n<\/metadata>\n        <\/record>","journals":null,"language":null,"relations":["http:\/\/dx.doi.org\/10.1016\/j.addr.2007.05.011"],"year":2007,"topics":["Crystal engineering","Crystallisation","Supramolecular chemistry","Polymorphism","Co-crystal","Solubility","Dissolution rate","Bioavailability","Low aqueous solubility"],"subject":["Article"],"fullText":null}